Free Trial
NASDAQ:WINT

Windtree Therapeutics (WINT) Stock Price, News & Analysis

$4.11
-0.14 (-3.30%)
(As of 05/22/2024 ET)
Today's Range
$4.03
$4.43
50-Day Range
$3.93
$7.83
52-Week Range
$3.72
$35.10
Volume
19,182 shs
Average Volume
43,951 shs
Market Capitalization
$2.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
WINT stock logo

About Windtree Therapeutics Stock (NASDAQ:WINT)

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitorfor the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has collaboration with Chang Gung University; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

WINT Stock Price History

WINT Stock News Headlines

Windtree Therapeutics Inc WINT
Windtree Therapeutics is dangerously low on cash
Windtree Therapeutics Announces Reverse Stock Split
Windtree Therapeutics Inc
See More Headlines
Receive WINT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/16/2024
Today
5/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:WINT
Employees
20
Year Founded
N/A

Profitability

Net Income
$-20,290,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$26.05 per share

Miscellaneous

Free Float
589,000
Market Cap
$2.42 million
Optionable
Not Optionable
Beta
0.62
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Craig E. FraserMr. Craig E. Fraser (Age 59)
    Chairman, President, CEO & Interim Principal Officer
    Comp: $567.2k
  • Mr. Eric L. Curtis M.B.A. (Age 56)
    Senior VP & COO
    Comp: $411.3k
  • Dr. Steven G. Simonson M.D. (Age 65)
    M.H.S, Senior VP & Chief Medical Officer
    Comp: $448k
  • Ms. Jamie McAndrew (Age 43)
    VP, Controller, Chief Accounting Officer & Corporate Secretary
  • Mr. George Cox (Age 72)
    Vice President of Technical Operations
  • Dr. Pratap Paruchuru
    Executive Director of Clinical Development
  • Ms. Tracy Rarick
    Head of Operations & Program Management

WINT Stock Analysis - Frequently Asked Questions

Should I buy or sell Windtree Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WINT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WINT, but not buy additional shares or sell existing shares.
View WINT analyst ratings
or view top-rated stocks.

How have WINT shares performed in 2024?

Windtree Therapeutics' stock was trading at $12.9420 at the beginning of 2024. Since then, WINT stock has decreased by 68.3% and is now trading at $4.1050.
View the best growth stocks for 2024 here
.

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics, Inc. (NASDAQ:WINT) announced its earnings results on Tuesday, April, 16th. The company reported ($13.31) earnings per share for the quarter.

When did Windtree Therapeutics' stock split?

Windtree Therapeutics's stock reverse split before market open on Monday, April 22nd 2024. The 1-18 reverse split was announced on Monday, April 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

How do I buy shares of Windtree Therapeutics?

Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:WINT) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners